Skip to main
IFRX

InflaRx (IFRX) Stock Forecast & Price Target

InflaRx (IFRX) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

InflaRx is a clinical-stage biotechnology company with a strong focus on developing anti-inflammatory therapeutics through C5a and C5aR inhibition. With its novel compounds, vilobelimab and izicopan, the company aims to selectively target the complement activation pathway and provide more effective and safer treatment options for a range of autoimmune and inflammatory diseases. Recent positive data from rivals and substantial funding through recent offerings further strengthen the company's outlook, and its pipeline expansion into AAV and renal diseases adds potential for further clinical progress.

Bears say

InflaRx is a clinical-stage biotechnology company focusing on developing a novel C5aR inhibitor, izicopan, in various inflammatory diseases. While their lead asset has shown promise in clinical trials, the upcoming Phase 3 trial's focus on efficacy endpoints and potential drug interactions with FDA may present challenges and potential delays. Additionally, competition from other companies targeting the same pathway may impact their success in the long-term.

InflaRx (IFRX) has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of InflaRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About InflaRx (IFRX) Forecast

Analysts have given InflaRx (IFRX) a Buy based on their latest research and market trends.

According to 6 analysts, InflaRx (IFRX) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

InflaRx (IFRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.